BioCentury | May 25, 2018
Clinical News
MimiVax reports Phase II data for glioblastoma immunotherapy
...in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago. MimiVax...
...and maintenance SurVaxM every 12 weeks. Final data from the trial are expected in 4Q18. MimiVax...
...The product has Orphan Drug designation in the U.S. to treat glioblastoma and multiple myeloma. MimiVax LLC...
...and maintenance SurVaxM every 12 weeks. Final data from the trial are expected in 4Q18. MimiVax...
...The product has Orphan Drug designation in the U.S. to treat glioblastoma and multiple myeloma. MimiVax LLC...
